Regeneron Pharmaceuticals (REGN) Competitors

Regeneron Pharmaceuticals logo
$673.60 -0.67 (-0.10%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$673.50 -0.10 (-0.01%)
As of 02/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGN vs. AMGN, VRTX, GILD, ALNY, BIIB, UTHR, INCY, BMRN, NBIX, and EXEL

Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.

Regeneron Pharmaceuticals vs.

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations.

Amgen has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.

Amgen currently has a consensus target price of $314.09, indicating a potential upside of 7.88%. Regeneron Pharmaceuticals has a consensus target price of $973.13, indicating a potential upside of 44.47%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
10 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.46
Regeneron Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.76

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$33.42B4.68$6.72B$7.5538.56
Regeneron Pharmaceuticals$14.20B5.21$3.95B$38.2817.60

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Amgen received 2 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 72.03% of users gave Amgen an outperform vote while only 66.93% of users gave Regeneron Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
AmgenOutperform Votes
1550
72.03%
Underperform Votes
602
27.97%
Regeneron PharmaceuticalsOutperform Votes
1548
66.93%
Underperform Votes
765
33.07%

In the previous week, Amgen had 1 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Amgen and 57 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.11 beat Regeneron Pharmaceuticals' score of 0.36 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
43 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Regeneron Pharmaceuticals
23 Very Positive mention(s)
2 Positive mention(s)
26 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Amgen's net margin of 12.24%. Amgen's return on equity of 176.32% beat Regeneron Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen12.24% 176.32% 11.71%
Regeneron Pharmaceuticals 31.07%16.32%12.76%

Summary

Regeneron Pharmaceuticals beats Amgen on 10 of the 19 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REGN vs. The Competition

MetricRegeneron PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$79.35B$6.98B$5.84B$9.14B
Dividend YieldN/A2.90%5.27%4.00%
P/E Ratio17.609.6826.2019.39
Price / Sales5.21297.61468.35124.16
Price / Cash15.8875.4646.1438.90
Price / Book2.525.527.275.05
Net Income$3.95B$123.25M$3.19B$222.74M
7 Day Performance-5.13%2.85%2.82%2.11%
1 Month Performance-4.24%2.19%4.59%2.33%
1 Year Performance-29.45%1.61%22.54%16.79%

Regeneron Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REGN
Regeneron Pharmaceuticals
4.8685 of 5 stars
$673.60
-0.1%
$973.13
+44.5%
-28.9%$79.35B$14.20B17.6013,450Dividend Announcement
AMGN
Amgen
4.4913 of 5 stars
$293.87
+0.1%
$314.09
+6.9%
+0.4%$157.93B$33.42B38.9226,700Insider Trade
Short Interest ↑
Positive News
VRTX
Vertex Pharmaceuticals
4.3265 of 5 stars
$468.13
-0.3%
$502.58
+7.4%
+9.8%$120.56B$9.87B-235.245,400Earnings Report
Analyst Forecast
Insider Trade
Analyst Revision
News Coverage
GILD
Gilead Sciences
4.785 of 5 stars
$95.44
-0.6%
$98.39
+3.1%
+42.5%$118.97B$27.12B1,060.6718,000Earnings Report
Analyst Forecast
Insider Trade
Short Interest ↓
Analyst Revision
ALNY
Alnylam Pharmaceuticals
4.547 of 5 stars
$272.47
-1.3%
$298.61
+9.6%
+56.2%$35.14B$2.09B-103.982,100Earnings Report
Analyst Forecast
Short Interest ↓
News Coverage
BIIB
Biogen
4.7968 of 5 stars
$141.49
+0.1%
$228.80
+61.7%
-37.8%$20.62B$9.61B12.797,570Earnings Report
Analyst Forecast
Options Volume
Analyst Revision
News Coverage
UTHR
United Therapeutics
4.4775 of 5 stars
$347.78
+0.0%
$382.08
+9.9%
+72.8%$15.53B$2.76B15.281,168Insider Trade
Analyst Revision
INCY
Incyte
4.561 of 5 stars
$69.30
-6.5%
$75.71
+9.2%
+21.6%$13.35B$3.70B495.032,524Earnings Report
Analyst Forecast
Short Interest ↑
Analyst Revision
BMRN
BioMarin Pharmaceutical
4.7627 of 5 stars
$63.67
-0.4%
$94.20
+48.0%
-24.6%$12.13B$2.42B38.133,401Analyst Upgrade
Positive News
NBIX
Neurocrine Biosciences
4.8915 of 5 stars
$116.90
-4.7%
$168.35
+44.0%
-12.7%$11.84B$2.36B35.531,400Analyst Forecast
Insider Trade
Short Interest ↓
EXEL
Exelixis
4.8344 of 5 stars
$33.92
+1.3%
$36.06
+6.3%
+71.7%$9.71B$1.83B21.791,310Earnings Report
Analyst Downgrade
Short Interest ↓
Analyst Revision

Related Companies and Tools


This page (NASDAQ:REGN) was last updated on 2/15/2025 by MarketBeat.com Staff
From Our Partners